We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Glucose Meter Evaluated for Neonatal Intensive Care

By LabMedica International staff writers
Posted on 17 Oct 2013
The monitoring of blood glucose in neonatal intensive care unit (NICU) patients is important in maintaining normoglycemia and reducing the risk of hypoglycemia. More...


Point-of-care testing (POCT) glucose meters provide short turnaround times but some have been reported to be affected by hematocrit interference and other biochemical or biological substances in their accuracy and performance.

Scientists at the Medical University of Vienna (Austria) tested 159 heparinized whole blood samples from NICU patients obtained for blood gas analysis. Accuracy (bias) of a new meter and analytical interferences were evaluated by comparing the results of the meter with the results of the blood gas analyzer routinely used for glucose measurements in this NICU setting.

Routine glucose measurements were performed at each hospital site using blood gas analyzers ABL 700 and ABL 835 (Radiometer Medical ApS, Copenhagen, Denmark). The blood gas analyzers were considered the appropriate reference method for comparing the performance of StatStrip Glucose POCT (Nova Biomedical; Waltham, MA, USA).

The results of glucose values covered the range of hypoglycemia to hyperglycemia, with glucose concentrations ranging from 13 mg/dL to 389 mg/dL. The results obtained for the Nova StatStrip Glucose POCT were not affected by the level of hematocrit, by sample pH or by medication. In the two children’s hospitals where the study was performed, the NICU patient population demonstrated a wide range of hematocrit levels even beyond the levels of the ranges claimed as not showing interferences in the product labeling of other glucose meters.

The authors concluded that the accuracy of the NOVA StatStrip Glucose meter results was not influenced by the varying hematocrit levels in the NICU patients, which validates the performance of the hematocrit correction that is in-built into the design of StatStrip Glucose. The StatStrip meter showed good clinical accuracy and performance for measuring and monitoring glucose levels in NICU patients, with special respect to preterm infants, and therefore can act as a perfect alternative to a blood gas analyzer for measuring blood glucose in NICU patients. The study was published on September 1, 2013, in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
Medical University of Vienna
Radiometer Medical ApS
Nova Biomedical


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The precision oncology test identifies patients most at risk of undergoing severe toxicity from treatment with 5FU/capecitabine (Photo courtesy of 123RF)

Precision Oncology Test Predicts Patient Toxicity Before Beginning Chemotherapy

5-fluorouracil (5FU) and capecitabine have been cornerstone chemotherapeutic agents for over four decades, effectively treating a variety of cancers. However, 5FU/capecitabine can cause varying degrees... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Mimix Reference Standards are cell-line derived to maintain genomic complexity and mimic patient material across molecular diagnostics workflows (Photo courtesy of Revvity)

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

Accurate diagnosis, including the identification of genomic markers, is essential for determining the most effective cancer treatments for patients. To ensure this, laboratories require reliable reference... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.